Depomed Completes Enrollment of Phase 3 Clinical Program of DM-1796 in Post-Herpetic Neuralgia.
Linked as:
Extract
Depomed Completes Enrollment of Phase 3 Clinical Program of DM-1796 in Post-Herpetic Neuralgia.
MENLO PARK, Calif. -- Depomed, Inc. (NASDAQ:DEPO) announced today that it has completed enrollment of the Phase 3 clinical trial of DM-1796 for the treatment of post-herpetic neuralgia.
"We are glad that we successfully arrived at another milestone that brings Depomed closer to potential milestone payments related to the devel...See the full content of this document
Sponsored links
